Opiant Pharmaceuticals – Consensus Indicates Potential 261.0% Upside

Broker Ratings

Opiant Pharmaceuticals with ticker code (OPNT) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 44 and 38 and has a mean target at 41.33. With the stocks previous close at 11.45 this indicates there is a potential upside of 261.0%. The 50 day moving average now sits at 12.35 and the 200 day moving average is 9.15. The market capitalisation for the company is $50m. You can visit the company’s website by visiting: http://www.opiant.com

Opiant Pharmaceuticals, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals in January 2016. Opiant Pharmaceuticals was founded in 2005 and is headquartered in Santa Monica, California.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index